Anti-inflammatory medicines such as aspirin, estrogen, and Fluimucil can improve the efficacy of existing schizophrenia treatments, according to results announced at the European College of Neuropsychopharmacology conference in Berlin.

Doctors have long believed that helping the immune system may benefit the treatment of schizophrenia, but until now there has been no conclusive evidence that this would be effective. Now a group of researchers at the University of Utrecht in the Netherlands has carried out a comprehensive meta-analysis of all robust studies on the effects of adding anti-inflammatories to antipsychotic medication. They conclude that anti-inflammatory medicines, such as aspirin, can add to the effective treatment of schizophrenia. 

Psychology and psychiatry have a big problem - they are trapped in the past. While most areas of medicine have moved beyond symptom-based diagnosis, the mental health community is instead adding new symptom-based diagnoses, and as a result the National Institute of Mental Health has declared that the newest Diagnostic and Statistical Manual of Mental Disorders should be considered little more than a glossary of terms.

To fix that, psychiatry needs to progress from symptom-based (e.g. antidepressant, antipsychotic etc.) to pharmacologically based (e.g. focusing on pharmacological target (serotonin, dopamine etc.) and the relevant mode of action. Not only is it more scientific, it will stop patient's wondering why they are getting an antipsychotic for simple anxiety.

Long-term daily use of Viagra can provide protection for the heart at different stages of heart disease, with few side effects, according to a new meta-analysis published in BMC Medicine. 

Scientists from the Sapienza University of Rome carried out a meta-analysis of randomized controlled trials by searching for articles published between January 2004 and May 2014 to deduce the effectiveness of  Phosphodiesterase-5 inhibitor
(PDE5i) in providing cardiac protection, and to find out whether it was well-tolerated and safe. They identified 24 suitable trials for analysis from four research databases: MEDLINE, EMBASE, Cochrane Library and SCOPUS. The trials involved 1622 patients from mixed populations who were treated with PDE5i or a placebo. 

A systemic disease that causes inflammation in the spinal joints and was thought to have affected members of the ancient Egyptian royal families may have been another condition, according to a new study published in Arthritis&Rheumatology.

The authors refutes claims of Ankylosing spondylitis in royals like King Amenhotep III (1390–1352 BC), finding instead a degenerative spinal condition called diffuse idiopathic skeletal hyperostosis (DISH) in royal Egyptian mummies from the 18th to early 20th Dynasties.

Without question American CO2 emissions have plummeted, even after being driven into more coal usage due to political concerns about nuclear energy. Cleaner natural gas made the difference but environmental critics say the energy emissions burden simply shifted to developing nations - poor people can't have air conditioning. 

Yet a new study in Nature Climate Change shows that environmentalists don't need to be criticizing the world's poor.  Improving household electricity access in India over the last 30 years contributed only marginally to the nation's total carbon emissions growth.   

New research into a rare pathogen has shown how a unique evolutionary trait allows it to infect even the healthiest of hosts through a smart solution to the body's immune response against it.

Scientists at the University of Birmingham have explained how a particular strain of a fungus, Cryptococcus gattii, responds to the human immune response and triggers a 'division of labour' in its invading cells, which can lead to life-threatening infections.